Therapies for the bone in mucopolysaccharidoses

Area of Science:

• Biochemistry
• Genetics
• Orthopedics

Background:

• Mucopolysaccharidoses (MPS) are genetic disorders characterized by glycosaminoglycan accumulation.
• This accumulation leads to multisystemic manifestations, including severe skeletal deformities and progressive disability.
• Patients often require multiple orthopedic surgeries due to progressive skeletal dysplasia.

Purpose of the Study:

• To provide an overview of current and emerging therapies for bone lesions in MPS.
• To discuss the impact of these therapies on skeletal dysplasia progression.
• To highlight the challenges in delivering effective treatments to bone tissue.

Main Methods:

• Review of existing literature on MPS therapies.
• Analysis of the efficacy of enzyme replacement therapy (ERT), hematopoietic stem cell transplantation (HSCT), and gene therapy.
• Discussion of the role of anti-inflammatory drugs in managing MPS bone disease.

Main Results:

• ERT, HSCT, and gene therapy offer potential for treating MPS bone disease.
• Delivery of therapeutic agents to avascular cartilage remains a significant challenge.
• Early intervention is crucial as skeletal dysplasia severity correlates with daily activity levels.

Conclusions:

• Improved therapies are urgently needed to prevent irreversible bone lesions in MPS.
• Targeted delivery of treatments to bone tissue is essential for therapeutic success.
• A multi-faceted approach, including early intervention, is key to managing MPS skeletal complications.